{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:26:16Z","timestamp":1764937576274,"version":"3.40.5"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,16]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Postoperative radiotherapy (PORT) is commonly used to treat patients with resected stage III non-small cell lung cancer (NSCLC), but its effectiveness remains uncertain. This retrospective cohort study aimed to investigate the impact of PORT on overall survival (OS) and evaluate its heterogeneity among subgroups of patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A total of 6305 patients with resected stage III NSCLC were included in this study from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching was conducted to balance baseline characteristics between the patients who received PORT and those who did not. OS was used as the primary outcome. Subgroup analysis was performed to identify which patient subgroups might benefit more from PORT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Overall, no significant difference was observed in OS between the 2 groups with or without propensity score matching. However, subgroup analysis demonstrated that PORT improved OS in patients with certain characteristics, including stage IIIA\/N2, stage IIIB, squamous cell carcinoma, tumor grade III-IV, or lymph node ratio (LNR)\u2005&gt;\u20051\/3. Multivariate analysis showed that several variables were associated with adverse prognostic factors for OS, such as marital status (others), race (white), male gender, squamous cell carcinoma, elderly age, advanced stage, poor histological differentiation grade, high LNR, and not receiving chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In patients with resected stage III NSCLC, PORT may not be beneficial for all patients. However, it may improve survival time in certain patient subgroups, such as those with stage IIIA\/N2, stage IIIB, squamous cell carcinoma, tumor grade III to IV, or LNR\u2005&gt;\u20051\/3. These findings provide important information for clinical decision-making and future research regarding the use of PORT in patients with resected stage III NSCLC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000034015","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T18:06:16Z","timestamp":1686938776000},"page":"e34015","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The impact of postoperative radiotherapy on the survival of patients with stage III non-small cell lung cancer: A CONSORT-compliant analysis using the SEER database"],"prefix":"10.1097","volume":"102","author":[{"given":"Kun","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Cardiothoracic Surgery, Xiangtan Central Hospital, Xiangtan, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Peng","sequence":"additional","affiliation":[{"name":"School of Medical Equipment and Management, Xiangtan Medicine and Health Vocational College, Xiangtan, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifeng","family":"Shuai","sequence":"additional","affiliation":[{"name":"Department of Radiology, Xiangtan Central Hospital, Xiangtan, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Radiology, Xiangtan Central Hospital, Xiangtan, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Xiangtan Central Hospital, Xiangtan, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2920-2648","authenticated-orcid":false,"given":"Sanhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Liuyang Chinese Medicine Hospital, Changsha, Hunan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1378\/chest.111.6.1710","article-title":"Revisions in the international system for staging lung cancer.","volume":"111","author":"Mountain","year":"1997","journal-title":"Chest"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/(SICI)1097-0142(19990715)86:2<265::AID-CNCR10>3.0.CO;2-B","article-title":"A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma.","volume":"86","author":"Dautzenberg","year":"1999","journal-title":"Cancer"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(98)06341-7","article-title":"Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials.","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.lungcan.2004.09.010","article-title":"Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis.","volume":"47","author":"Burdett","year":"2005","journal-title":"Lung Cancer"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ijrobp.2008.01.044","article-title":"Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non\u2013small-cell lung cancer treated with adjuvant chemotherapy: the Adjuvant Navelbine International Trialist Association (ANITA) randomized trial.","volume":"72","author":"Douillard","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1200\/JCO.2005.04.6110","article-title":"Postoperative radiotherapy for stage II or III non\u2013small-cell lung cancer using the surveillance, epidemiology, and end results database.","volume":"24","author":"Lally","year":"2006","journal-title":"J Clin Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/JTO.0000000000000406","article-title":"Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non\u2013small-cell lung cancer using the national cancer database.","volume":"10","author":"Corso","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/JTO.0000000000000411","article-title":"Postoperative radiotherapy is associated with better survival in non\u2013small cell lung cancer with involved N2 lymph nodes: results of an analysis of the national cancer data base.","volume":"10","author":"Mikell","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2014.58.5380","article-title":"Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the national cancer data base.","volume":"33","author":"Robinson","year":"2015","journal-title":"J Clin Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaoncol.2021.1910","article-title":"Effect of postoperative radiotherapy for patients with pIIIA-N2 non\u2013small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT-C randomized clinical trial.","volume":"7","author":"Hui","year":"2021","journal-title":"JAMA Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1470-2045(21)00654-9","article-title":"Postoperative radiotherapy in resected N2 non-small-cell lung cancer: lung ART.","volume":"23","author":"Hendriks","year":"2022","journal-title":"Lancet Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cllc.2021.08.007","article-title":"Role of postoperative radiotherapy in the management for resected NSCLC \u2013 decision criteria in clinical routine pre- and post-LungART.","volume":"22","author":"S\u00fcveg","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3816\/CLC.2007.n.005","article-title":"A phase III study of surgical resection and paclitaxel\/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non\u2013small-cell lung cancer: cancer and leukemia group B 9734.","volume":"8","author":"Perry","year":"2007","journal-title":"Clin Lung Cancer"},{"key":"R15-20250504","first-page":"CD002142","article-title":"Postoperative radiotherapy for non-small cell lung cancer.","volume":"10","author":"Burdett","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"5004s","DOI":"10.1158\/1078-0432.CCR-05-9010","article-title":"Localized non-small cell lung cancer: adjuvant radiotherapy in the era of effective systemic therapy.","volume":"11","author":"Bogart","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4149\/neo_2018_181213N965","article-title":"The effect of postoperative radiotherapy on the survival of patients with resectable stage III-N2 non-small-cell lung cancer: a systematic review and meta-analysis.","volume":"66","author":"Zhang","year":"2019","journal-title":"Neoplasma"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.21037\/jtd.2017.10.47","article-title":"Optimal managements of stage IIIA (N2) non-small cell lung cancer patients: a population-based survival analysis.","volume":"9","author":"Pang","year":"2017","journal-title":"J Thorac Dis"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/jso.25308","article-title":"The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-small cell lung cancer.","volume":"119","author":"Yuan","year":"2019","journal-title":"J Surg Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"329","DOI":"10.21149\/10115","article-title":"Squamous cell lung cancer: genomic evolution and personalized therapy.","volume":"61","author":"Cardona","year":"2019","journal-title":"Salud Publica Mex"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1186\/s12885-019-6141-z","article-title":"Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis.","volume":"19","author":"Su","year":"2019","journal-title":"BMC Cancer"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2478\/raon-2020-0070","article-title":"Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: a preferential benefit for squamous cell carcinoma.","volume":"55","author":"Tian","year":"2020","journal-title":"Radiol Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/JTO.0b013e318292c53e","article-title":"Lymph node ratio may predict the benefit of postoperative radiotherapy in non\u2013small-cell lung cancer.","volume":"8","author":"Urban","year":"2013","journal-title":"J Thorac Oncol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.jtho.2018.08.2021","article-title":"Survival patterns for patients with resected N2 non\u2013small cell lung cancer and postoperative radiotherapy: a prognostic scoring model and heat map approach.","volume":"13","author":"Deng","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/cam4.2937","article-title":"Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: a single-center, retrospective study.","volume":"9","author":"Wei","year":"2020","journal-title":"Cancer Med"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/j.cllc.2022.05.006","article-title":"The significance of lymph node ratio and total lymph nodes examined in determining the indications of adjuvant radiation in pN2 non-small cell lung cancer.","volume":"23","author":"Zhu","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.","volume":"350","author":"Arriagada","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:09:43Z","timestamp":1746320983000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":28,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034015","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,6,16]]}}}